Literature DB >> 33033142

Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study.

Neige Marie Yvanne Journy1,2, Wael Salem Zrafi3,2,4, Stéphanie Bolle4, Brice Fresneau3,2,5, Claire Alapetite6,7, Rodrigue Setcheou Allodji3,2, Delphine Berchery8, Nadia Haddy3,2, Isao Kobayashi3,2, Martine Labbé3,2, Hélène Pacquement9, Claire Pluchart10, Boris Schwartz3,2, Vincent Souchard3,2, Cécile Thomas-Teinturier3,2,11, Cristina Veres3,2,12, Giao Vu-Bezin3,2, Ibrahima Diallo3,2, Florent de Vathaire3,2.   

Abstract

BACKGROUND: Childhood or adolescent cancer survivors are at increased risks of subsequent primary neoplasms (SPN) of the central nervous system (CNS) after cranial irradiation. In a large multicentric cohort, we investigated clinical and therapeutic factors associated with the long-term risk of CNS SPN, and quantified the dose-response relationships.
METHODS: We selected all CNS SPN cases diagnosed up to 2016 among members of the French Childhood Cancer Survivor Study at least 5 years after first cancer diagnosis in 1946-2000. Four controls per case were randomly selected within the cohort and matched by sex, year of/age at first cancer diagnosis, and follow-up time. On the basis of medical and radiological reports, cumulative radiation doses received to the SPN or matched location were retrospectively estimated using mathematical phantoms. We computed conditional logistic regression models.
RESULTS: Meningioma risk significantly increased with higher radiation doses [excess OR per Gy (EOR/Gy) = 1.377; P < 0.001; 86 cases; median latency time = 30 years], after adjustment for reported genetic syndromes and first CNS tumor. It was higher among youngest individuals at first cancer diagnosis, but did not vary with follow-up time. On the opposite, radiation-related glioma risk (EOR/Gy = 0.049; P = 0.11; 47 cases; median latency time = 17 years) decreased over time (P for time effect = 0.05). There was a significant association between meningioma risk and cumulative doses of alkylating agents, but no association with growth hormone therapy.
CONCLUSIONS: The surveillance of patients with cranial irradiation should continue beyond 30 years after treatment. IMPACT: The identified risk factors may inform long-term surveillance strategies. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33033142     DOI: 10.1158/1055-9965.EPI-20-0735

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

1.  Identifying causal relationships of cancer treatment and long-term health effects among 5-year survivors of childhood cancer in Southern Sweden.

Authors:  Anders Holst; Jan Ekman; Magnus Petersson-Ahrholt; Thomas Relander; Thomas Wiebe; Helena M Linge
Journal:  Commun Med (Lond)       Date:  2022-03-02

Review 2.  Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.

Authors:  Margaret C S Boguszewski; Cesar L Boguszewski; Wassim Chemaitilly; Laurie E Cohen; Judith Gebauer; Claire Higham; Andrew R Hoffman; Michel Polak; Kevin C J Yuen; Nathalie Alos; Zoltan Antal; Martin Bidlingmaier; Beverley M K Biller; George Brabant; Catherine S Y Choong; Stefano Cianfarani; Peter E Clayton; Regis Coutant; Adriane A Cardoso-Demartini; Alberto Fernandez; Adda Grimberg; Kolbeinn Guðmundsson; Jaime Guevara-Aguirre; Ken K Y Ho; Reiko Horikawa; Andrea M Isidori; Jens Otto Lunde Jørgensen; Peter Kamenicky; Niki Karavitaki; John J Kopchick; Maya Lodish; Xiaoping Luo; Ann I McCormack; Lillian Meacham; Shlomo Melmed; Sogol Mostoufi Moab; Hermann L Müller; Sebastian J C M M Neggers; Manoel H Aguiar Oliveira; Keiichi Ozono; Patricia A Pennisi; Vera Popovic; Sally Radovick; Lars Savendahl; Philippe Touraine; Hanneke M van Santen; Gudmundur Johannsson
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

3.  Editorial: History of Growth Hormone: Animal to Human.

Authors:  Edward O Reiter; Laurie E Cohen; Alan D Rogol
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-03       Impact factor: 5.555

Review 4.  Growth Hormone Deficiency and Treatment in Childhood Cancer Survivors.

Authors:  Netanya I Pollock; Laurie E Cohen
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-22       Impact factor: 5.555

5.  Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma.

Authors:  Makoto Ohno; Yasuji Miyakita; Masamichi Takahashi; Shunsuke Yanagisawa; Yukie Tamura; Daisuke Kawauchi; Miyu Kikuchi; Hiroshi Igaki; Akihiko Yoshida; Kaishi Satomi; Yuko Matsushita; Koichi Ichimura; Yoshitaka Narita
Journal:  Radiat Oncol       Date:  2022-05-03       Impact factor: 4.309

Review 6.  Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice.

Authors:  Margaret C S Boguszewski; Adriane A Cardoso-Demartini; Cesar Luiz Boguszewski; Wassim Chemaitilly; Claire E Higham; Gudmundur Johannsson; Kevin C J Yuen
Journal:  Pituitary       Date:  2021-07-25       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.